Discover 1,249 paid clinical trials in Murfreesboro, Tennessee. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,249
Featured
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
for
Migraine
Location: Nashville TN, Huntsville AL, Atlanta GA, Lexington KY,
Sponsor: AbbVie
Sex: All
Age: 6 - 17
Code: NCT05125302
Phase3, Recruiting
Featured
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
for
Episodic Migraine
Location: Nashville TN, Huntsville AL, Newburgh IN, Cincinnati OH,
Sponsor: AbbVie
Sex: All
Age: 6 - 17
Code: NCT05711394
Phase3, Recruiting
Featured
A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
for
Acute Myeloid Leukemia
Location: Nashville TN, Dallas TX, Valhalla NY, Palo Alto CA
Sponsor: AbbVie
Sex: All
Age: 0 - 17
Code: NCT07306832
Phase1, Recruiting
Featured
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
for
Advanced Prostate Cancer, Metastatic Prostate Cancer
Location: Nashville TN, Scottsdale AZ
Sponsor: Genentech, Inc.
Sex: Male
Age: 18+
Code: NCT07567846
Phase1, Phase2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
for
Non-segmental Vitiligo
Location: Murfreesboro TN, Birmingham AL, Indianapolis IN,
Sponsor: Novartis Pharmaceuticals
Sex: All
Age: 18 - 70+
Code: NCT07431177
Phase2, Recruiting
Active & Responsive
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
for
Psoriatic Arthritis, Axial Spondyloarthritis
Location: Murfreesboro TN, Jackson TN, Vandalia OH, Rock Hill SC,
Sponsor: UCB Biopharma SRL
Sex: All
Age: 18+
Code: NCT07290036
Phase1, Recruiting
Active & Responsive
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
for
Psoriasis, Overweight or Obesity
Location: Smyrna TN, Bowling Green KY, Douglasville GA,
Sponsor: Eli Lilly and Company
Sex: All
Age: 18+
Code: NCT06857942
Recruiting
Active & Responsive
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
for
Heart Failure With Preserved Ejection Fraction,
Location: Tullahoma TN, Huntsville AL, Oak Ridge TN, Powell TN,
Sponsor: Amgen
Sex: All
Age: 18 - 70+
Code: NCT07037459
Phase3, Recruiting
Active & Responsive
Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)
for
Idiopathic Pulmonary Fibrosis (IPF)
Location: Franklin TN, Rock Hill SC, DuBois PA, Denison TX,
Sponsor: PureTech
Sex: All
Age: 40+
Code: NCT07284602
Phase3, Recruiting
Active & Responsive
A Study of RSLV-132 in Females With Sjögren's Disease
for
Primary Sjögren Syndrome
Location: Nashville TN, Charlotte NC, Salisbury NC, Chicago IL,
Sponsor: Resolve Therapeutics
Sex: Female
Age: 18 - 70+
Code: NCT06440525
Phase2, Recruiting
Active & Responsive
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer